Company intelligence / Profile preview

Arrinex

Menlo Park, California, United Statesstryker.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Arrinex developed the ClariFix cryoablation device to treat chronic rhinitis by targeting the posterior nasal nerve. Multiple clinical trials demonstrated safety and efficacy of this minimally invasive approach. The company was acquired by Stryker in early 2019 to expand Stryker’s ENT portfolio. The ClariFix system has been commercialized for treating chronic rhinitis; additional work on therapies for minor symptomatic nasal septal deviation has been reported.

Therapeutic areas: OtherImmunology
Modalities: DeviceCryotherapy device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ClariFix

Commercial

Indications: Chronic rhinitis

Partnerships

Not specified; now part of Stryker’s Neurotechnology business unit

Beyond the preview

Go deeper on Arrinex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arrinex.

Explore the full profile